Barclays
SLXP

Barclays’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Barclays’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-437,300
Closed -$75.2M – 7497
2015
Q1 		$75.2M Buy
437,300
+336,900
+336% +$49.5M 0.09% 211
2014
Q4 		$11.4M Buy
100,400
+26,800
+36% +$3.25M 0.01% 1093
2014
Q3 		$11.5M Buy
73,600
+51,300
+230% +$7.44M 0.01% 1070
2014
Q2 		$2.74M Sell
22,300
-29,100
-57% -$3.22M ﹤0.01% 2303
2014
Q1 		$5.29M Buy
51,400
+40,800
+385% +$4.18M 0.01% 1660
2013
Q4 		$943K Buy
10,600
+9,600
+960% +$766K ﹤0.01% 3462
2013
Q3 		$66K Sell
1,000
-2,000
-67% -$138K ﹤0.01% 5916
2013
Q2 		$198K Buy
+3,000
New +$172K ﹤0.01% 5191

Other funds holding SLXP

MMG
Monetary Management Group St Louis, Missouri $419M AUM 29.55% 1-Year Est. Return

Barclays's SLXP Position: Q2 2015 in Review

Barclays sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 303,956 shares — an estimated $52.3M sold.

Barclays first reported a position in SLXP in Q2 2013 and held it in 8 quarters. The position peaked at $52.3M in Q1 2015. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

  • Barclays reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
  • Barclays sold 303,956 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $52.3M.
  • Barclays first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 8 quarters.
  • Barclays's SALIX PHARMACEUTICALS LTD DEL position peaked at $52.3M in Q1 2015.
  • 1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on Barclays's 13F filing for Q2 2015, filed 14 Aug 2015.